Clinical Medications WorksheetsGeneric Namelinezolid

Trade NameZyvox

Classificationanti-infectives, oxazolidinones

Dose600mg

RouteIV

Time/frequencyQ 12 hrs

PeakEnd of infusion

OnsetRapid

Duration12 hr

Normal dosage range600 mg every 12 hr for 14-28 daysRATE: Administer over 30-120 minutes.

Why is your patient getting this medicationComplicated skin/skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Uncomplicated skin/skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains)

For IV meds, compatibility with IV drips and/or solutionsDo not piggyback into other IV lines. Flush line before and after infusion. Y-Site Incompatibility: amphotericin B, chlorpromazine, diazepam, pentamidine, phenytoin

Mechanism of action and indications(Why med ordered)Inhibits bacterial protein synthesis at the level of the 23S ribosome of the 50S subunit. Bactericidal action against streptococci; bacteriostatic action against enterococci and staphylococci.

Nursing Implications (what to focus on) Contraindications/warnings/interactionsHypersensitivity

Common side effectsPSEUDOMEMBRANOUS COLITIS

Interactions with other patient drugs, OTC or herbal medicines (ask patient specifically)Xopenex: Patients should be closely monitored for blood pressure and pulse rate changes during coadministration of beta-adrenergic agonists with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-adrenergic agonists.Because of monoamine oxidase inhibitory properties, consumption of large amounts of foods or beverages containing tyramine should be avoided (↑ risk of pressor response.)

Lab value alterations caused by medicineMay cause bone marrow suppression, anemia, leukopenia, pancytopenia. Monitor CBC and platelet count weekly, especially in patients who are at risk for increased bleeding, who have pre-existing bone marrow suppression, who receive concurrent medications that may cause myelosuppression, or who may require >2 weeks of therapy. Discontinue therapy if bone marrow suppression occurs or worsens. May cause ↑ AST, ALT, LDH, alkaline phosphatase and BUN Be sure to teach the patient the following about this medicationAdvise patients taking oral linezolid to take as directed, for full course of therapy, even if feeling better. Take missed doses as soon as remembered unless almost time for next dose; do not double dose. Instruct patient to avoid large quantities of foods or beverages containing tyramine (May cause hypertensive response). Instruct patient to notify health care professional if patient has a history of hypertension and before patient takes other Rx, OTC, or herbal products, especially cold remedies, decongestants, or antidepressants. Advise patient to notify health care professional if no improvement is seen in a few days.

Nursing Process- Assessment(Pre-administration assessment)Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and during therapy. Obtain specimens for culture and sensitivity prior to initiating therapy. First dose may be given before receiving

AssessmentWhy would you hold or not give this med?recurrent nausea and vomiting, unexplained acidosis or low bicarbonate levels. If optic neuropathy occurs therapy should be reconsidered

EvaluationCheck after givingImprovement of infection